Rajeev Saggar Sells 71,381 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 71,381 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $27.00, for a total transaction of $1,927,287.00. Following the transaction, the insider owned 176,549 shares of the company’s stock, valued at approximately $4,766,823. This represents a 28.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Monday, October 13th, Rajeev Saggar sold 5,327 shares of Liquidia stock. The shares were sold at an average price of $23.41, for a total value of $124,705.07.
• On Thursday, August 28th, Rajeev Saggar sold 20,000 shares of Liquidia stock. The shares were sold at an average price of $27.85, for a total value of $557,000.00.
• On Thursday, August 28th, Rajeev Saggar sold 20,000 shares of Liquidia stock. The stock was sold at an average price of $27.85, for a total value of $557,000.00.

Liquidia Price Performance

Shares of LQDA stock traded up $0.49 on Friday, hitting $26.09. 1,824,264 shares of the company’s stock were exchanged, compared to its average volume of 2,002,429. The company has a 50 day moving average of $24.52 and a 200 day moving average of $19.70. The stock has a market cap of $2.27 billion, a P/E ratio of -18.12 and a beta of 0.12. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 2.41. Liquidia Corporation has a 12 month low of $9.71 and a 12 month high of $29.94.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The business’s revenue was up 1106.7% on a year-over-year basis. On average, equities research analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia in the third quarter valued at about $30,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the second quarter worth approximately $25,000. Hurley Capital LLC bought a new stake in Liquidia in the first quarter valued at approximately $32,000. GAMMA Investing LLC increased its position in Liquidia by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after purchasing an additional 1,173 shares during the period. Finally, Quarry LP acquired a new stake in Liquidia during the 1st quarter valued at approximately $79,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on LQDA shares. Jefferies Financial Group restated a “buy” rating and issued a $45.00 target price on shares of Liquidia in a research report on Monday. Raymond James Financial reiterated a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a research note on Tuesday. Wells Fargo & Company started coverage on Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Finally, Needham & Company LLC lifted their price target on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and an average target price of $38.56.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).